Literature DB >> 8255780

Oncogene activation of HIV-LTR-driven expression via the NF-kappa B binding sites.

J T Bruder1, G Heidecker, T H Tan, J C Weske, D Derse, U R Rapp.   

Abstract

The Raf-1 proto-oncogene product is a highly regulated serine/threonine kinase that functions in signal transduction downstream from growth factor receptors and upstream from nuclear proto-oncogene products. Using a transient cotransfection assay we have found that activated Raf-1 activates expression from the HIV-LTR. Analysis of a series of 5' deletion and point mutations revealed the NF-kappa B motifs as the Raf-responsive element in the HIV-LTR. Moreover, Raf-BXB activated expression from heterologous promoters driven by the HIV NF-kappa B binding sites. In addition to Raf, we show that v-Src, v-H-Ras and v-Mos activate HIV-LTR expression through the NF-kappa B binding sites and v-H-Ras-induced HIV-LTR expression is mediated by Raf-1. These findings may have implications for the involvement of the cellular homologues of these oncogenes in the switch from latent to productive infection by HIV in response to T-cell activation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255780      PMCID: PMC310641          DOI: 10.1093/nar/21.22.5229

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  43 in total

1.  Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells.

Authors:  M Wigler; S Silverstein; L S Lee; A Pellicer; Y c Cheng; R Axel
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

2.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

3.  Expression of raf oncogenes activates the PEA1 transcription factor motif.

Authors:  C Wasylyk; B Wasylyk; G Heidecker; M Huleihel; U R Rapp
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

4.  Definition of the human raf amino-terminal regulatory region by deletion mutagenesis.

Authors:  V P Stanton; D W Nichols; A P Laudano; G M Cooper
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

5.  Expression and characterization of the trans-activator of HTLV-III/LAV virus.

Authors:  C M Wright; B K Felber; H Paskalis; G N Pavlakis
Journal:  Science       Date:  1986-11-21       Impact factor: 47.728

6.  An inducible transcription factor activates expression of human immunodeficiency virus in T cells.

Authors:  G Nabel; D Baltimore
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

7.  Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity.

Authors:  D K Morrison; D R Kaplan; U Rapp; T M Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro.

Authors:  P Dent; W Haser; T A Haystead; L A Vincent; T M Roberts; T W Sturgill
Journal:  Science       Date:  1992-09-04       Impact factor: 47.728

9.  Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B.

Authors:  G E Griffin; K Leung; T M Folks; S Kunkel; G J Nabel
Journal:  Nature       Date:  1989-05-04       Impact factor: 49.962

10.  Transforming but not immortalizing oncogenes activate the transcription factor PEA1.

Authors:  C Wasylyk; J L Imler; B Wasylyk
Journal:  EMBO J       Date:  1988-08       Impact factor: 11.598

View more
  14 in total

1.  Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.

Authors:  A G Bassuk; R T Anandappa; J M Leiden
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

2.  Binding of human immunodeficiency virus type 1 to CD4 induces association of Lck and Raf-1 and activates Raf-1 by a Ras-independent pathway.

Authors:  W Popik; P M Pitha
Journal:  Mol Cell Biol       Date:  1996-11       Impact factor: 4.272

3.  UV-A-induced decrease in nuclear factor-kappaB activity in human keratinocytes.

Authors:  M Djavaheri-Mergny; M P Gras; J L Mergny; L Dubertret
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

4.  Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression.

Authors:  J T Bruder; I Kovesdi
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway.

Authors:  X Yang; D Gabuzda
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation.

Authors:  B Baumann; C K Weber; J Troppmair; S Whiteside; A Israel; U R Rapp; T Wirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Ras activation of genes: Mob-1 as a model.

Authors:  P Liang; L Averboukh; W Zhu; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter.

Authors:  E Flory; A Hoffmeyer; U Smola; U R Rapp; J T Bruder
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and particpates in the activation of NF-kappa B.

Authors:  L Folgueira; A Algeciras; W S MacMorran; G D Bren; C V Paya
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF-kappaB enhancer element into a GABP binding site.

Authors:  K Verhoef; R W Sanders; V Fontaine; S Kitajima; B Berkhout
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.